Division of Rheumatology, Department of Medicine.
Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery.
Rheumatology (Oxford). 2022 May 30;61(6):2424-2431. doi: 10.1093/rheumatology/keab807.
To estimate the incidence and time-to-classification of SLE by the 1997 ACR (ACR97) criteria, the SLICC criteria, and the European Alliance of Associations for Rheumatology/ACR (EULAR/ACR) criteria.
We identified all incident SLE cases from 2000-2018 in the well-defined Olmsted County population. Clinical data included in the ACR97, SLICC and EULAR/ACR criteria were manually abstracted from medical records. All incident cases met at least one of the three classification criteria. Time-to-classification was estimated from the first documented lupus-attributable disease manifestation to the time of criteria fulfilment by each of the three definitions. Annual incidence rates were age or age/sex adjusted to the 2000 US population.
Of 139 incident cases there were 126 cases by the EULAR/ACR criteria, corresponding to an age/sex-adjusted incidence of 4.5 per 100 000 population (95% CI: 3.7, 5.2). The age/sex-incidence was higher than that of the SLICC criteria (113 cases; 4.0 per 100 000 [95% CI: 3.3, 4.7], P = 0.020) and the ACR97 (92 cases; 3.3 per 100 000 [95% CI: 2.6, 3.9], P < 0.001). The median time from first disease manifestation to criteria fulfilment was shorter for the EULAR/ACR criteria (29.4 months) than the ACR97 criteria (47.0 months, P < 0.001) and similar to the SLICC criteria (30.6 months, P = 0.83).
The incidence of SLE was higher by the EULAR/ACR criteria compared with the ACR97 and the SLICC criteria, and the EULAR/ACR criteria classified patients earlier that the ACR97 criteria but similar to the SLICC criteria.
根据 1997 年美国风湿病学会(ACR)标准、简化的疾病活动指数(SLICC)标准和欧洲抗风湿病联盟/ACR(EULAR/ACR)标准,评估系统性红斑狼疮(SLE)的发病率和分类时间。
我们从明尼苏达州奥姆斯特德县明确界定的人群中确定了 2000 年至 2018 年所有新诊断的 SLE 病例。ACR97、SLICC 和 EULAR/ACR 标准中包含的临床数据是从病历中手动摘录的。所有新诊断的病例均符合这三个分类标准中的至少一个。通过三个定义中的每一个来估计分类时间,即从首次记录的狼疮相关疾病表现到符合标准的时间。发病率按年龄或年龄/性别调整至 2000 年美国人口。
在 139 例新诊断的病例中,有 126 例符合 EULAR/ACR 标准,这相当于年龄/性别调整后的发病率为每 100 000 人口 4.5 例(95%可信区间:3.7,5.2)。年龄/性别发病率高于 SLICC 标准(113 例;每 100 000 人 4.0 例[95%可信区间:3.3,4.7],P=0.020)和 ACR97 标准(92 例;每 100 000 人 3.3 例[95%可信区间:2.6,3.9],P<0.001)。从首次疾病表现到符合标准的中位数时间,EULAR/ACR 标准(29.4 个月)短于 ACR97 标准(47.0 个月,P<0.001),与 SLICC 标准(30.6 个月,P=0.83)相似。
与 ACR97 和 SLICC 标准相比,EULAR/ACR 标准诊断的 SLE 发病率更高,并且 EULAR/ACR 标准比 ACR97 标准更早地诊断患者,但与 SLICC 标准相似。